NCT03573544 2024-02-22This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.OBI Pharma, IncPhase 1/2 Terminated54 enrolled 16 charts